Jordan T.Klimek

Associate

Washington + 1.202.879.3765

Jordan Klimek represents clients in intellectual property matters, with a particular focus on innovative companies in the biopharmaceutical sector. Jordan has experience with issues arising under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act, and he has participated in all stages of the litigation process. He has also represented companies before the Patent Trial and Appeal Board (PTAB) and has advised innovator companies on regulatory and patent matters in preparation for Hatch-Waxman litigation.

While in law school, Jordan received the Robert C. Watson Award for Best Student Article from the American Intellectual Property Law Association for "Patents as Regulations: How the America Invents Act and the Seminole Rock Doctrine Could Change Claim Construction after Teva v. Sandoz."

Before joining Jones Day in 2020, Jordan served as a law clerk to Judge Alan D. Lourie on the United States Court of Appeals for the Federal Circuit.

Experience

  • Merck asserts patent infringement claims under Hatch-Waxman Act relating to Bridion® against 16 generic drug makersJones Day is representing Merck & Co., Inc. in Hatch-Waxman patent infringement actions against 16 generic drug maker defendant groups, relating to the defendant groups' submissions of Abbreviated New Drug Applications to the FDA seeking approval of generic versions of Bridion®, a first-in-class agent for the reversal of certain types of neuromuscular blockade in adults undergoing surgery.
  • Allergan defends JUVEDERM® patents against nine IPR petitions filed by ProlleniumJones Day is representing Allergan, Inc. before the U.S. Patent Trial and Appeal Board ("PTAB") on nine IPR petitions filed by Prollenium challenging multiple patents covering certain of Allergan's JUVEDERM® products, hyaluronic acid-based dermal fillers that include the anesthetic lidocaine.